| abstract |
Formula (I) Embedded image Wherein R 1 is H; C 1-24 alkyl; C 2-24 alkenyl; C 6-24 aryl; C 5-20 heteroaromatic ring; optionally selected from the group comprising O, N, or S It is C 3-20 non-aromatic ring containing 1-3 three heteroatoms; R 3 and R 4 are for example in each case independently H; C 1-24 alkyl; C 2-24 alkenyl; A C 6-24 aryl; a C 5-18 heteroaromatic ring; optionally a C 3-20 non-aromatic ring containing 1-3 heteroatoms selected from the group comprising O, N, or S; ) R 6; -C (O) oR 6; -C (O) NHR 6; a, or an amino acid radical or a dipeptide or tripeptide chain or analogs thereof, wherein the amino acid radical, Glu, Gly, Ala, Val, Leu, Il e, Pro, Phe, Tyr, Trp, Ser, Thr, Cys, Met, is selected from the group comprising Asn and Gln, and it in each case, optionally terminated by -R 7; R 6 is in each case H, C 1-20 alkyl, C 2-20 alkenyl, C 0-20 alkyl-C 6-24 aryl, C 0-20 alkyl-C 5-20 heteroaromatic ring, optionally O, N or S Is a C 3-20 non-aromatic ring containing 1-3 heteroatoms selected from the group comprising: and R 7 is in each case C 1-20 alkyl, C 2-20 alkenyl, C 6 -10 aryl, a C5-20 heteroaromatic ring, optionally a C3-20 non-aromatic ring containing 1-3 heteroatoms selected from the group comprising O, N or S, -C (O) R 6 , —C (O) OR 6 ; and X and Y are each independently Br, Cl, I, F, OH, OR 3 or NR 3 R 4 , and at least one of X and Y is , NR 3 R 4 ], or a pharmaceutically acceptable salt thereof, is useful in treating patients with cancer. |